NEO-HYDELTRASOL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NEO-HYDELTRASOL (NEO-HYDELTRASOL).
Prednisolone, a glucocorticoid, binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators, including cytokines, prostaglandins, and leukotrienes. It also inhibits phospholipase A2 and reduces immune cell activity.
| Metabolism | Primarily hepatic via CYP3A4; prednisolone is a metabolite of prednisone. Conjugation with glucuronic acid and sulfate; renal excretion of metabolites. |
| Excretion | Renal: 50–80% as unchanged drug and metabolites (primarily as glucuronide and sulfate conjugates). Fecal/biliary: minor (<10%). |
| Half-life | Terminal elimination half-life: 2.5–3.5 hours (adults). Note: The biologic half-life (duration of anti-inflammatory effect) is 18–36 hours due to persistence of glucocorticoid receptor-mediated effects. |
| Protein binding | 70–80% bound to corticosteroid-binding globulin (CBG, transcortin) and albumin. |
| Volume of Distribution | Vd: 0.4–0.6 L/kg. Indicates moderate extracellular distribution. |
| Bioavailability | Bioavailability: intravenous 100%; oral 70–90% (peak at 1–2 hours); topical/intra-articular: systemic absorption minimal (if applied to intact skin), but can be significant in denuded areas or with high doses. |
| Onset of Action | Intravenous: immediate (minutes). Intra-articular: 1–2 days. Oral: 1–2 hours. Topical: variable (hours). |
| Duration of Action | Duration of clinical effect: 12–36 hours depending on dose and route; intra-articular can last 1–3 weeks. Biologic effects persist longer than plasma levels. |
| Molecular Weight | 360.44 |
4-20 mg intramuscularly, intravenously, intra-articularly, or intrasynovially every 12-24 hours; maximum initial dose 40 mg.
| Dosage form | OINTMENT |
| Renal impairment | No dose adjustment required for GFR >30 mL/min; for GFR 10-30 mL/min, use with caution and consider dose reduction by 25%; for GFR <10 mL/min, avoid use. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated. |
| Pediatric use | 0.04-0.3 mg/kg/day intramuscularly or intravenously divided every 6-12 hours; not to exceed 2 mg/kg/day. |
| Geriatric use | Use lowest effective dose; monitor for fluid retention, hypertension, and hyperglycemia; initiate at 4 mg/day and titrate slowly. |
| 1st trimester | Corticosteroids are generally avoided in the first trimester unless necessary. Prednisolone is preferred due to its metabolism by placental 11β-HSD2. High doses may be associated with oral clefts (OR 1.63). |
| 2nd trimester | Use with caution. Monitor for maternal glucose intolerance and fetal growth restriction. Prednisolone is preferred for its lower fetal exposure. |
| 3rd trimester | Use with caution. Prolonged use may cause fetal adrenal suppression, growth restriction, and preterm delivery. Taper if possible before delivery. |
Clinical note
Comprehensive clinical and safety monograph for NEO-HYDELTRASOL (NEO-HYDELTRASOL).
| Placental transfer | Prednisolone is extensively metabolized by placental 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) to inactive metabolites, resulting in <10% transfer to fetal circulation. At high maternal doses (>80 mg/day), significant fetal levels may occur. |
| Breastfeeding |
■ FDA Black Box Warning
No FDA boxed warning is specified for NEO-HYDELTRASOL; however, corticosteroids as a class may increase risk of fungal infections, and intrathecal administration is contraindicated.
| Serious Effects |
Systemic fungal infectionsKnown hypersensitivity to prednisolone or any componentAdministration of live or live-attenuated vaccinesIdiopathic thrombocytopenic purpura (IM administration)
| Precautions | Immunosuppression and increased susceptibility to infections, Adrenal suppression with prolonged use, Cushing's syndrome, Osteoporosis, Gastrointestinal perforation (especially in patients with diverticulitis or recent GI surgery), Myopathy, Ocular effects (cataracts, glaucoma), HPA axis suppression with rapid withdrawal |
| Food/Dietary | No significant food interactions. However, patients on long-term corticosteroids should maintain a diet adequate in calcium and potassium, and avoid excessive sodium intake. |
Loading safety data…
| Prednisolone is excreted into breast milk in small amounts. Doses up to 40 mg/day are considered compatible with breastfeeding. To minimize infant exposure, avoid nursing for 4 hours after a dose. Monitor infant for signs of adrenal suppression (e.g., poor feeding, lethargy). |
| Lactation Rating | L2 (Safer, but caution required) |
| Teratogenic Risk | First trimester: Increased risk of cleft palate (odds ratio 1.3-3.0) with systemic use; risk unclear with topical/ocular use. Second trimester: Possible growth restriction, adrenal suppression. Third trimester: Risk of neonatal adrenal suppression, premature delivery, low birth weight. |
| Fetal Monitoring | Monitor maternal blood pressure, glucose, infection signs. Fetal growth ultrasounds; assess for intrauterine growth restriction. Neonatal adrenal function at birth. |
| Fertility Effects | May impair ovulation in women; reversible upon discontinuation. No known direct effect on spermatogenesis. |
| Clinical Pearls | Neo-Hydeltrasol is a combination of neomycin and prednisolone acetate. Use with caution in patients with viral, fungal, or tubercular infections. Prolonged use may lead to secondary ocular infections, increased intraocular pressure, and cataract formation. Monitor intraocular pressure in patients with glaucoma. Do not use in patients with epithelial herpes simplex keratitis (dendritic keratitis). |
| Patient Advice | Shake the bottle well before each use. · Do not touch the dropper tip to any surface to avoid contamination. · Do not wear contact lenses during treatment unless instructed by your doctor. · Report any vision changes, eye pain, or worsening redness immediately. · Use exactly as prescribed; do not stop abruptly without consulting your doctor. |